Beam Therapeutics Inc. Common Stock (BEAM) News
Latest headlines that mention BEAM, newest first · each headline opens the original publisher
- Last price
- $24.90
- Day change
- +4.67%
- Next earnings
- 2026-11-03
BEAM headlines
latest coverageThe gene-editing biotech stock is down more than 12% this year.
Beam Therapeutics' growing pipeline could reward patient investors.
Prime Medicine won a legal battle with Beam Therapeutics on Wednesday. Prime shares jumped while Beam stock skidded. The post Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle appeared first on Investor's Business Daily .
Are there significant gains ahead for one (or both) of these innovative biotechs?
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
BEAM news alerts
Get an alert by email or push when a new headline mentions BEAM.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.